ST. PETERSBURG, Russia, July 10, 2014 /PRNewswire/ --
On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD. The Company is developing a unique project called MabNext. Within the scope of MabNext project BIOCAD develops a number of innovative drugs based on monoclonal antibodies for treatment of cancer and autoimmune diseases. The ceremony took place at the International Exhibition "Innoprom 2014" in Ekaterinburg.
According to the Russian Ministry of Health, in the last 12 years the number of new cases of malignant tumors has increased by 11%. The steady increase in the number of cancer patients is a global trend. According to the International Agency for Research on Cancer, in the next 20 years the number of new oncology patients in the world will reach the figure of 22 million cases per year. Therefore, Russia and the rest of the world are so desperately in need of new effective drugs that will help to overcome serious illnesses and save millions of lives.
BIOCAD is developing a wide portfolio of innovative products based on monoclonal antibodies for treatment of diseases such as breast cancer, colorectal cancer, lung cancer, melanoma, multiple sclerosis, rheumatoid arthritis and psoriasis.
"Now the country is undergoing fundamental changes regarding availability of modern drugs for its people. Thanks to the support of Ministry of Industry and Trade, Ministry of Health, Ministry of Economic D
Copyright©2014 PR Newswire.
All rights reserved